Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

Mise à jour : Il y a 4 ans
Référence : NCT01235975

Femme et Homme

  • | Pays :
  • Lebanon
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

This study evaluates the immunogenicity and safety of the meningococcal conjugate vaccine GSK 134612 given as single dose to healthy adults 56 years or older compared to the meningococcal polysaccharide vaccine MencevaxACWYTM.


Critère d'inclusion

  • Infections, Meningococcal

Liens